Get the Stockscreener App
3.735
10.36%
0.355
Omniab Inc stock is traded at $3.735, with a volume of 17.53M.
It is up +10.36% in the last 24 hours and up +75.94% over the past month.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
See More
Previous Close:
$3.38
Open:
$4.185
24h Volume:
17.53M
Relative Volume:
19.15
Market Cap:
$543.18M
Revenue:
$28.94M
Net Income/Loss:
$-54.29M
P/E Ratio:
-8.0374
EPS:
-0.4647
Net Cash Flow:
$-26.02M
1W Performance:
+10.03%
1M Performance:
+75.94%
6M Performance:
+118.13%
1Y Performance:
+85.57%
1-Day Range:
$3.72
$4.2899
1-Week Range:
$3.295
$4.2899
52-Week Range:
$1.30
$4.2899
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
3.736 | 491.42M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
515.63 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.01 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
991.71 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
213.05 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.25 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - benzinga.com
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com Canada
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
Why is OmniAb stock surging today? - Investing.com
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company - Finviz
OmniAb raises 2026 cash guidance on licensing activity - Investing.com
Whitefort Capital group reports 7.1% OmniAb (OABI) ownership in amended filing - Stock Titan
OmniAb (OABI) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI - marketbeat.com
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OABI Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI) - simplywall.st
OmniAb (NASDAQ:OABI) Sets New 1-Year HighTime to Buy? - MarketBeat
Is Now The Time To Look At Buying OmniAb, Inc. (NASDAQ:OABI)? - Moomoo
HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI) - marketbeat.com
OmniAb Company Profile & Introduction - Moomoo
Price to sales forward of OmniAb, Inc. – NASDAQ:OABIW - TradingView
OmniAb (NASDAQ:OABI) Jumps After Strong Quarterly Update - Kalkine Media
OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $7 to $11 - Moomoo
OmniAb (OABI) Stock Jumps As Milestones Cut Losses But Risks Linger - Sahm
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
OmniAb, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:OABI) 2026-08-07 - Seeking Alpha
Stifel Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $9 - news.futunn.com
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
OmniAb, Inc. (OABIW) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
OmniAb Inc (OABI) Stock News Today - TradingKey
OmniAb Inc reports results for the quarter ended June 30Earnings Summary - TradingView
OmniAb Q2 2026 slides: revenue surges on milestones, guidance raised By Investing.com - Investing.com South Africa
OmniAb Q2 2026 Earnings Call Transcript - MarketBeat
H.C. Wainwright Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $11 - Moomoo
OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
OmniAb Inc (OABI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
TD Cowen Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $3 - Moomoo
OmniAb Q2 Earnings Call Highlights - TradingView
OmniAb Inc (OABI) (Q2 2026) Earnings Call Highlights: Revenue Surges 243% as Two Programs Leap ... - Yahoo Finance
Earnings call transcript: OmniAb beats Q2 2026 estimates and lifts outlook - Investing.com
OmniAb, Inc. (OABI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
OABI: Revenue growth and clinical progress drove improved outlook and reduced net loss - TradingView
OmniAb Q2 2026 slides: revenue surges on milestones, guidance raised - Investing.com
OABI: Strong Q2 revenue growth and raised 2026 guidance reflect robust partner and technology momentum - TradingView
OmniAb Q2 2026 slides: revenue surges 244%, guidance raised - Investing.com
OmniAb Q2 revenue beats analyst estimates, outlook raised - TradingView
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):